GSE114883 romidepsin T cell 0 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE114883_romidepsin_T cell_0_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE114883_romidepsin_T cell_0_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE114883_romidepsin_T cell_0_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE114883_romidepsin_T cell_0_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

acetylserotonin O-methyltransferase like

Gene

Rho GTPase activating protein 23

Gene

H3 clustered histone 7

Gene

SRC kinase signaling inhibitor 1

Gene

GOLGA2 pseudogene 7

Gene

BAIAP2 divergent transcript

Gene

colorectal neoplasia differentially expressed

Gene

deleted in lymphocytic leukemia 1

Gene

DPPA2 upstream binding RNA

Gene

H2B clustered histone 20, pseudogene

  • Gene

    acetylserotonin O-methyltransferase like


  • Gene

    Rho GTPase activating protein 23


  • Gene

    H3 clustered histone 7


  • Gene

    SRC kinase signaling inhibitor 1


  • Gene

    GOLGA2 pseudogene 7


  • Gene

    BAIAP2 divergent transcript


  • Gene

    colorectal neoplasia differentially expressed


  • Gene

    deleted in lymphocytic leukemia 1


  • Gene

    DPPA2 upstream binding RNA


  • Gene

    H2B clustered histone 20, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.